<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04004481</url>
  </required_header>
  <id_info>
    <org_study_id>OsijekUH</org_study_id>
    <nct_id>NCT04004481</nct_id>
  </id_info>
  <brief_title>Metabolites of Tramadol in the Postoperative Surgical Patients</brief_title>
  <acronym>METRAS</acronym>
  <official_title>Metabolites of Tramadol in the Postoperative Surgical Patients Admitted in the ICU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osijek University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Josip Juraj Strossmayer University of Osijek</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Osijek University Hospital</source>
  <brief_summary>
    <textblock>
      Tramadol is opioid analgesic widely used to treat moderate to severe pain. It is metabolized&#xD;
      by cytochrome CYP2D6 into two major metabolites: pharmacologically active metabolite&#xD;
      O-desmethyltramadol (M1) and inactive N-desmethyltramadol (M2), respectively. Tramadol&#xD;
      kinetics in a population of patients undergoing major abdominal surgical procedures, and in&#xD;
      patients with a greater or lesser degree of organic failure, is still not well researched.&#xD;
      The investigators will measure plasma concentrations of tramadol and its metabolites after&#xD;
      usual tramadol doses in ICU patients after major abdominal surgery. Also analgesic affect and&#xD;
      side effect of tramadol will be recorded.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The blood samples for the CYP2D6 gene polymorphism analysis will be taken from all patients&#xD;
      included in the study. The patients will be categorized as slow (PM), normal (NM) or&#xD;
      ultra-fast metabolizers (UM) of tramadol using analysis of the CYP2D6 phenotype. Standard&#xD;
      laboratory findings including red blood cells, urea, creatinine, and cholinesterase will be&#xD;
      done before surgery.&#xD;
&#xD;
      The patients will receive 500 mg of tramadol intravenously divided into 5 doses during the&#xD;
      first 24 postoperative hours in the ICU. The plasma concentrations of tramadol,&#xD;
      O-desmethyltramadol and N-desmethyltramadol will be measured 1, 2 and 4 hours after the first&#xD;
      dose, and immediately before the 2nd, 3rd and 5th dose. There will therefore be 6&#xD;
      measurements of tramadol and its metabolites.&#xD;
&#xD;
      The analgesic effect of tramadol will be measured in awake patients with Numeric Rating Scale&#xD;
      - NRS (0 - without pain, 10 - strong pain) 30 minutes before and 30 minutes after tramadol&#xD;
      administration. The NRS value of 3 or less will be considered as adequate analgesia. In case&#xD;
      of inadequate analgesia rescue analgesic (morphine) will be used according to the local&#xD;
      protocol.&#xD;
&#xD;
      In unconscious patients the analgesic effect of tramadol will be tested by Critical Care Pain&#xD;
      Observation Tool (CPOT). The CPOT value of less than 2 will be considered as adequate&#xD;
      analgesia. In case of inadequate analgesia rescue analgesic (morphine) will be used according&#xD;
      to the local protocol. During the first 24 hours side effect of tramadol, such as nausea,&#xD;
      vomiting and new respiratory depression will be recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 25, 2019</start_date>
  <completion_date type="Actual">March 13, 2020</completion_date>
  <primary_completion_date type="Actual">February 28, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Concentration of Tramadol and Tramadol Metabolites With Respect to Metabolic Phenotype</measure>
    <time_frame>1, 2, and 4 hours after first dose and immediately before 2nd, 3rd, and 5th dose, up to 24 hours</time_frame>
    <description>The plasma concentrations of tramadol, O-desmethyltramadol (ODT) and N-desmethyltramadol (NDT) will be measured 1, 2 and 4 hours after the first dose of 100 mg tramadol i.v., and immediately before the 2nd, 3rd and 5th dose. There will therefore be 6 measurements of tramadol and its metabolites.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analgesic Effect of Tramadol Measured by Numeric Rating Scale (NRS)</measure>
    <time_frame>Before each dose of tramadol and 30 minutes after tramadol dose, up to 24 hours</time_frame>
    <description>The analgesic effect of tramadol will be measured in awake patients with Numeric Rating Scale (NRS, 0 - without pain, 10 - the worst pain) 30 minutes before and 30 minutes after tramadol administration. The NRS value of 3 or less will be considered as adequate analgesia. In case of inadequate analgesia morphine will be used according to the local protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic Effect of Tramadol Measured by Critical Care Pain Observation Tool (CPOT)</measure>
    <time_frame>Pain was assessed before and 30 minutes after each tramadol dose, up to 24 hours.</time_frame>
    <description>In unconsciousness patents, the analgesic effect of tramadol will be tested by Critical Care Pain Observation Tool (CPOT). Highest score on a scale is 8 (worst pain) and lowest is 0 (no pain). The CPOT value of less than 2 will be considered as adequate analgesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Nausea and Vomiting After Tramadol</measure>
    <time_frame>Nausea and vomiting was assessed during first 30 minutes after tramadol administration</time_frame>
    <description>Nausea and/or vomiting during treatment with tramadol in ICU will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Respiratory Depression After Tramadol</measure>
    <time_frame>Respiratory depression was observed up to 30 minutes after tramadol administration</time_frame>
    <description>Respiratory depression after tramadol is considered to be any drop in saturation below 90% or drop in respiratory rate below 10/min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU Stay</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Length of stay in ICU will be recorded and correlated with standard laboratory values and tramadol and metabolites concentration.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Abdominal Surgery</condition>
  <condition>Respiratory Failure</condition>
  <condition>Renal Failure</condition>
  <condition>Liver Dysfunction</condition>
  <condition>Multiorgan Failure</condition>
  <arm_group>
    <arm_group_label>Adult patients undergoing major open abdominal surgery</arm_group_label>
    <description>Observational study. In the patients undergoing major open abdominal surgery for cancer tramadol will be used for postoperative analgesia. In the postoperative period parent compound and metabolites of tramadol will be measured. Postoperative analgesia and adverse effects will be registered and compared between CYP2D6 phenotypes observed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Postoperative analgesia using tramadol</intervention_name>
    <description>Tramadol 100 mg will be given to the patients in the postoperative period.</description>
    <arm_group_label>Adult patients undergoing major open abdominal surgery</arm_group_label>
    <other_name>Morphine for rescue analgesia</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      CYP2D6 polymorphism will be done from DNA isolated from white cells.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The patients undergoing major open abdominal cancer surgery in Osijek University Hospital&#xD;
        who are admitted in the ICU after surgery, age between 18 and 90 years, BMI &gt;18 and &lt;35,&#xD;
        who signed the informed consent will be included in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients after major abdominal surgery will be observed.&#xD;
&#xD;
          -  surgical interventions requiring a laparotomy and involving resection of the organs of&#xD;
             the digestive system&#xD;
&#xD;
          -  postoperative ICU admission.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergic reaction to tramadol&#xD;
&#xD;
          -  patients under 18 years old&#xD;
&#xD;
          -  patient over 90 years old&#xD;
&#xD;
          -  BMI &lt;18 and &gt;35&#xD;
&#xD;
          -  laparoscopic surgery&#xD;
&#xD;
          -  chronic therapy with tramadol, cimetidine, paroxetine, pimozide, metoclopramide,&#xD;
             amiodarone, olanzapine, chlorpromazine, fluphenazine, haloperidol, thioridazine,&#xD;
             risperidone and clozapine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nenad Neskovic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osijek University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Osijek</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <reference>
    <citation>Yang Y, Botton MR, Scott ER, Scott SA. Sequencing the CYP2D6 gene: from variant allele discovery to clinical pharmacogenetic testing. Pharmacogenomics. 2017 May;18(7):673-685. doi: 10.2217/pgs-2017-0033. Epub 2017 May 4. Review.</citation>
    <PMID>28470112</PMID>
  </reference>
  <reference>
    <citation>Qiao W, Yang Y, Sebra R, Mendiratta G, Gaedigk A, Desnick RJ, Scott SA. Long-Read Single Molecule Real-Time Full Gene Sequencing of Cytochrome P450-2D6. Hum Mutat. 2016 Mar;37(3):315-23. doi: 10.1002/humu.22936. Epub 2015 Dec 18.</citation>
    <PMID>26602992</PMID>
  </reference>
  <reference>
    <citation>Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923. Review.</citation>
    <PMID>15509185</PMID>
  </reference>
  <reference>
    <citation>de Moraes NV, Lauretti GR, Coelho EB, Godoy AL, Neves DV, Lanchote VL. Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain. Fundam Clin Pharmacol. 2016 Apr;30(2):153-61. doi: 10.1111/fcp.12168. Epub 2015 Dec 11.</citation>
    <PMID>26947771</PMID>
  </reference>
  <reference>
    <citation>Xu J, Zhang XC, Lv XQ, Xu YY, Wang GX, Jiang B, Cai L, Cai XJ. Effect of the cytochrome P450 2D6*10 genotype on the pharmacokinetics of tramadol in post-operative patients. Pharmazie. 2014 Feb;69(2):138-41.</citation>
    <PMID>24640604</PMID>
  </reference>
  <reference>
    <citation>Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin Pharmacol Ther. 2007 Jul;82(1):41-7. Epub 2007 Mar 14.</citation>
    <PMID>17361124</PMID>
  </reference>
  <reference>
    <citation>Candiotti KA, Birnbach DJ, Lubarsky DA, Nhuch F, Kamat A, Koch WH, Nikoloff M, Wu L, Andrews D. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? Anesthesiology. 2005 Mar;102(3):543-9.</citation>
    <PMID>15731591</PMID>
  </reference>
  <reference>
    <citation>Bosilkovska M, Walder B, Besson M, Daali Y, Desmeules J. Analgesics in patients with hepatic impairment: pharmacology and clinical implications. Drugs. 2012 Aug 20;72(12):1645-69. doi: 10.2165/11635500-000000000-00000.</citation>
    <PMID>22867045</PMID>
  </reference>
  <reference>
    <citation>Rijkenberg S, Stilma W, Bosman RJ, van der Meer NJ, van der Voort PHJ. Pain Measurement in Mechanically Ventilated Patients After Cardiac Surgery: Comparison of the Behavioral Pain Scale (BPS) and the Critical-Care Pain Observation Tool (CPOT). J Cardiothorac Vasc Anesth. 2017 Aug;31(4):1227-1234. doi: 10.1053/j.jvca.2017.03.013. Epub 2017 Mar 15.</citation>
    <PMID>28800982</PMID>
  </reference>
  <reference>
    <citation>Severgnini P, Pelosi P, Contino E, Serafinelli E, Novario R, Chiaranda M. Accuracy of Critical Care Pain Observation Tool and Behavioral Pain Scale to assess pain in critically ill conscious and unconscious patients: prospective, observational study. J Intensive Care. 2016 Nov 7;4:68. eCollection 2016.</citation>
    <PMID>27833752</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 25, 2019</study_first_submitted>
  <study_first_submitted_qc>June 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <results_first_submitted>April 19, 2021</results_first_submitted>
  <results_first_submitted_qc>June 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 9, 2021</results_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tramadol</keyword>
  <keyword>CYP2D6 polymorphism</keyword>
  <keyword>analgesia</keyword>
  <keyword>intensive care</keyword>
  <keyword>organ failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Multiple Organ Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT04004481/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Adult Patients Undergoing Major Open Abdominal Surgery</title>
          <description>Observational study. In the patients undergoing major open abdominal surgery tramadol will be used for postoperative analgesia. In the postoperative period parent compound and metabolites of tramadol will be measured. Postoperative analgesia and adverse effects will be registered and compared between CYP2D6 phenotypes observed and in regards to systemic inflammation and preoperative cholinesterase activity.&#xD;
Postoperative analgesia using tramadol: Tramadol 100 mg will be given to the patients in the postoperative period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adult Patients Undergoing Major Open Abdominal Surgery</title>
          <description>Observational study. In the patients undergoing major open abdominal surgery for cancer tramadol will be used for postoperative analgesia. In the postoperative period parent compound and metabolites of tramadol will be measured. Postoperative analgesia and adverse effects will be registered and compared between CYP2D6 phenotypes observed.&#xD;
Postoperative analgesia using tramadol: Tramadol 100 mg will be given to the patients in the postoperative period.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" lower_limit="59" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.1" lower_limit="22.9" upper_limit="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ASA status</title>
          <description>ASA I: A normal healthy patient; ASA II: A patient with mild systemic disease; ASA III: A patient with severe systemic disease; ASA IV: A patient with severe systemic disease that is a constant threat to life; ASA V: A moribund patient who is not expected to survive without the operation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>ASA II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASA III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASA IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASA V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CYP2D6 polymorphism</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>*1/*4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>*1/*1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>*1/*4xN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>*4/*4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>*1/*3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>*1/*1xN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Metabolic phenotype</title>
          <description>Metabolic phenotype was determined according to the CYP2D6 diplotype polymorphism.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extensive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ultrafast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Concentration of Tramadol and Tramadol Metabolites With Respect to Metabolic Phenotype</title>
        <description>The plasma concentrations of tramadol, O-desmethyltramadol (ODT) and N-desmethyltramadol (NDT) will be measured 1, 2 and 4 hours after the first dose of 100 mg tramadol i.v., and immediately before the 2nd, 3rd and 5th dose. There will therefore be 6 measurements of tramadol and its metabolites.</description>
        <time_frame>1, 2, and 4 hours after first dose and immediately before 2nd, 3rd, and 5th dose, up to 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Concentration</title>
            <description>Median of tramadol concentration in 6 measurements point in postoperative 24 hours</description>
          </group>
          <group group_id="O2">
            <title>ODT Concentration in Poor Metabolizers (PM)</title>
            <description>Median ODT concentration in 6 measurements point in postoperative 24 hours in PM</description>
          </group>
          <group group_id="O3">
            <title>ODT Concentration in Intermediate Metabolizers (IM)</title>
            <description>Median ODT concentration in 6 measurements point in postoperative 24 hours in IM</description>
          </group>
          <group group_id="O4">
            <title>ODT Concentration in Extensive Metabolizers (EM)</title>
            <description>Median ODT concentration in 6 measurements point in postoperative 24 hours in EM</description>
          </group>
          <group group_id="O5">
            <title>ODT Concentration in Ultrafast Metabolizers (UM)</title>
            <description>Median ODT concentration in 6 measurements point in postoperative 24 hours in UM</description>
          </group>
          <group group_id="O6">
            <title>NDT Concentration in Poor Metabolizers (PM)</title>
            <description>Median NDT concentration in 6 measurements point in postoperative 24 hours in PM</description>
          </group>
          <group group_id="O7">
            <title>NDT Concentration in Intermediate Metabolizers (IM)</title>
            <description>Median NDT concentration in 6 measurements point in postoperative 24 hours in IM</description>
          </group>
          <group group_id="O8">
            <title>NDT Concentration in Extensive Metabolizers (EM)</title>
            <description>Median NDT concentration in 6 measurements point in postoperative 24 hours in EM</description>
          </group>
          <group group_id="O9">
            <title>NDT Concentration in Ultrafast Metabolizers (UM)</title>
            <description>Median NDT concentration in 6 measurements point in postoperative 24 hours in UM</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentration of Tramadol and Tramadol Metabolites With Respect to Metabolic Phenotype</title>
          <description>The plasma concentrations of tramadol, O-desmethyltramadol (ODT) and N-desmethyltramadol (NDT) will be measured 1, 2 and 4 hours after the first dose of 100 mg tramadol i.v., and immediately before the 2nd, 3rd and 5th dose. There will therefore be 6 measurements of tramadol and its metabolites.</description>
          <units>mcg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="22"/>
                <count group_id="O8" value="22"/>
                <count group_id="O9" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1st measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="372.7" lower_limit="250.6" upper_limit="535.7"/>
                    <measurement group_id="O2" value="7.05" lower_limit="4.52" upper_limit="7.05"/>
                    <measurement group_id="O3" value="17.1" lower_limit="6.3" upper_limit="38.1"/>
                    <measurement group_id="O4" value="40.9" lower_limit="21.9" upper_limit="53.9"/>
                    <measurement group_id="O5" value="13.8"/>
                    <measurement group_id="O6" value="11.7" lower_limit="7.6" upper_limit="11.7"/>
                    <measurement group_id="O7" value="4.5" lower_limit="3.5" upper_limit="11.1"/>
                    <measurement group_id="O8" value="4.76" lower_limit="3.5" upper_limit="19.1"/>
                    <measurement group_id="O9" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270.6" lower_limit="201.6" upper_limit="447.9"/>
                    <measurement group_id="O2" value="7.6" lower_limit="4.5" upper_limit="7.6"/>
                    <measurement group_id="O3" value="15.7" lower_limit="7.3" upper_limit="39.6"/>
                    <measurement group_id="O4" value="46.7" lower_limit="23.6" upper_limit="64.3"/>
                    <measurement group_id="O5" value="19.4"/>
                    <measurement group_id="O6" value="15.3" lower_limit="9.2" upper_limit="15.3"/>
                    <measurement group_id="O7" value="6.1" lower_limit="3.9" upper_limit="12.2"/>
                    <measurement group_id="O8" value="5.2" lower_limit="3.5" upper_limit="22"/>
                    <measurement group_id="O9" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232.1" lower_limit="153.5" upper_limit="369.8"/>
                    <measurement group_id="O2" value="10" lower_limit="4.6" upper_limit="10"/>
                    <measurement group_id="O3" value="20.2" lower_limit="12.5" upper_limit="40.4"/>
                    <measurement group_id="O4" value="46.4" lower_limit="31" upper_limit="72.6"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="28.9" lower_limit="12.3" upper_limit="28.9"/>
                    <measurement group_id="O7" value="9.1" lower_limit="5.3" upper_limit="14.7"/>
                    <measurement group_id="O8" value="8.5" lower_limit="3.6" upper_limit="22.9"/>
                    <measurement group_id="O9" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4th measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181.2" lower_limit="122.9" upper_limit="270.2"/>
                    <measurement group_id="O2" value="12.4" lower_limit="5.2" upper_limit="12.4"/>
                    <measurement group_id="O3" value="19.1" lower_limit="11.4" upper_limit="47.8"/>
                    <measurement group_id="O4" value="38.1" lower_limit="30.3" upper_limit="74.5"/>
                    <measurement group_id="O5" value="25.1"/>
                    <measurement group_id="O6" value="31.2" lower_limit="15.7" upper_limit="31.2"/>
                    <measurement group_id="O7" value="9.6" lower_limit="5.1" upper_limit="20.7"/>
                    <measurement group_id="O8" value="9.7" lower_limit="3.5" upper_limit="23.9"/>
                    <measurement group_id="O9" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5th measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300.1" lower_limit="191.8" upper_limit="417.6"/>
                    <measurement group_id="O2" value="19.1" lower_limit="10.7" upper_limit="19.1"/>
                    <measurement group_id="O3" value="36.6" lower_limit="21.2" upper_limit="71.4"/>
                    <measurement group_id="O4" value="75.1" lower_limit="46.3" upper_limit="117.6"/>
                    <measurement group_id="O5" value="58.2"/>
                    <measurement group_id="O6" value="71.4" lower_limit="43" upper_limit="71.4"/>
                    <measurement group_id="O7" value="20.2" lower_limit="10.5" upper_limit="37.2"/>
                    <measurement group_id="O8" value="19" lower_limit="7.4" upper_limit="45.6"/>
                    <measurement group_id="O9" value="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6th measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="408.5" lower_limit="273.8" upper_limit="677.8"/>
                    <measurement group_id="O2" value="29.7" lower_limit="23.9" upper_limit="29.7"/>
                    <measurement group_id="O3" value="51.7" lower_limit="25.7" upper_limit="93.5"/>
                    <measurement group_id="O4" value="97.4" lower_limit="52.6" upper_limit="139"/>
                    <measurement group_id="O5" value="61.9"/>
                    <measurement group_id="O6" value="180.5" lower_limit="124.9" upper_limit="180.5"/>
                    <measurement group_id="O7" value="34.9" lower_limit="18.5" upper_limit="69.9"/>
                    <measurement group_id="O8" value="34.4" lower_limit="18.6" upper_limit="72.5"/>
                    <measurement group_id="O9" value="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analgesic Effect of Tramadol Measured by Numeric Rating Scale (NRS)</title>
        <description>The analgesic effect of tramadol will be measured in awake patients with Numeric Rating Scale (NRS, 0 - without pain, 10 - the worst pain) 30 minutes before and 30 minutes after tramadol administration. The NRS value of 3 or less will be considered as adequate analgesia. In case of inadequate analgesia morphine will be used according to the local protocol.</description>
        <time_frame>Before each dose of tramadol and 30 minutes after tramadol dose, up to 24 hours</time_frame>
        <population>Pain was assessed by the NRS scale in patients who were awake.</population>
        <group_list>
          <group group_id="O1">
            <title>Median NRS Score Before Tramadol Administration</title>
            <description>NRS score value in awake patients before tramadol administration in 5 measurement point</description>
          </group>
          <group group_id="O2">
            <title>Median NRS Score After Tramadol Administration</title>
            <description>NRS score value in awake patients after tramadol administration in 5 measurement point</description>
          </group>
        </group_list>
        <measure>
          <title>Analgesic Effect of Tramadol Measured by Numeric Rating Scale (NRS)</title>
          <description>The analgesic effect of tramadol will be measured in awake patients with Numeric Rating Scale (NRS, 0 - without pain, 10 - the worst pain) 30 minutes before and 30 minutes after tramadol administration. The NRS value of 3 or less will be considered as adequate analgesia. In case of inadequate analgesia morphine will be used according to the local protocol.</description>
          <population>Pain was assessed by the NRS scale in patients who were awake.</population>
          <units>score on scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1st pain assessment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="3" upper_limit="9"/>
                    <measurement group_id="O2" value="5" lower_limit="3.5" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd pain assessment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="3" upper_limit="6.75"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd pain assessment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="2.25" upper_limit="5"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4th pain assessment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5th pain assessment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analgesic Effect of Tramadol Measured by Critical Care Pain Observation Tool (CPOT)</title>
        <description>In unconsciousness patents, the analgesic effect of tramadol will be tested by Critical Care Pain Observation Tool (CPOT). Highest score on a scale is 8 (worst pain) and lowest is 0 (no pain). The CPOT value of less than 2 will be considered as adequate analgesia.</description>
        <time_frame>Pain was assessed before and 30 minutes after each tramadol dose, up to 24 hours.</time_frame>
        <population>All unconscious patients had low CPOT values and were therefore not suitable for statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Median CPOT Score Before Tramadol Administration</title>
            <description>CPOT score value in awake patients before tramadol administration in 5 measurement point</description>
          </group>
          <group group_id="O2">
            <title>Median CPOT Score After Tramadol Administration</title>
            <description>CPOT score value in awake patients after tramadol administration in 5 measurement point</description>
          </group>
        </group_list>
        <measure>
          <title>Analgesic Effect of Tramadol Measured by Critical Care Pain Observation Tool (CPOT)</title>
          <description>In unconsciousness patents, the analgesic effect of tramadol will be tested by Critical Care Pain Observation Tool (CPOT). Highest score on a scale is 8 (worst pain) and lowest is 0 (no pain). The CPOT value of less than 2 will be considered as adequate analgesia.</description>
          <population>All unconscious patients had low CPOT values and were therefore not suitable for statistical analysis.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1st assessment point</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd assessment point</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd assessment point</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4th assessment point</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5th assessment point</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Nausea and Vomiting After Tramadol</title>
        <description>Nausea and/or vomiting during treatment with tramadol in ICU will be recorded.</description>
        <time_frame>Nausea and vomiting was assessed during first 30 minutes after tramadol administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PONV in EM</title>
            <description>We monitored the incidence of PONV with respect to metabolic phenotype.</description>
          </group>
          <group group_id="O2">
            <title>PONV in IM</title>
            <description>We monitored the incidence of PONV with respect to metabolic phenotype.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Nausea and Vomiting After Tramadol</title>
          <description>Nausea and/or vomiting during treatment with tramadol in ICU will be recorded.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Respiratory Depression After Tramadol</title>
        <description>Respiratory depression after tramadol is considered to be any drop in saturation below 90% or drop in respiratory rate below 10/min.</description>
        <time_frame>Respiratory depression was observed up to 30 minutes after tramadol administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Number of Patients With Postoperative Respiratory Depression</title>
            <description>We examined the occurrence of tramadol-induced respiratory depression in the first 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Respiratory Depression After Tramadol</title>
          <description>Respiratory depression after tramadol is considered to be any drop in saturation below 90% or drop in respiratory rate below 10/min.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of ICU Stay</title>
        <description>Length of stay in ICU will be recorded and correlated with standard laboratory values and tramadol and metabolites concentration.</description>
        <time_frame>Up to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Plasma Cholinesterase Activity</title>
            <description>Preoperative plasma cholinesterase activity &lt; 4244 U/L</description>
          </group>
          <group group_id="O2">
            <title>Normal Plasma Cholinesterase Activity</title>
            <description>Preoperative plasma cholinesterase activity &gt; 4244 U/L</description>
          </group>
        </group_list>
        <measure>
          <title>Length of ICU Stay</title>
          <description>Length of stay in ICU will be recorded and correlated with standard laboratory values and tramadol and metabolites concentration.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <desc>Postoperative nausea and/or vomiting</desc>
      <group_list>
        <group group_id="E1">
          <title>PONV in EM</title>
          <description>We monitored the incidence of PONV with respect to metabolic phenotype.</description>
        </group>
        <group group_id="E2">
          <title>PONV in IM</title>
          <description>We monitored the incidence of PONV with respect to metabolic phenotype.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>PONV</sub_title>
                <description>Postoperative nausea and/or vomiting</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="22"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nenad Neskovic</name_or_title>
      <organization>University hospital Osijek</organization>
      <phone>+385996787250</phone>
      <email>nneskov@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

